When that becomes an affordable alternative test, maybe they will, it is not today.... perhaps you should write to the CDC. Bottom line, is we still test for may things which are vague precursor events and they have helped greatly, if not an absolute test for something. Like the PSA test for Prostate specific antigen. Remember that detection of early stage disease is the goal, not finite determination of every individual that will definitively get it. We have to sift out of a population of 300 million people those most at risk, so that they can end up in accelerated monitoring programs for the earliest detection of actual disease events, when survival is the greatest. Trying to test that many people with a finite, expensive test is never going to be in the game.

Since we have diverged significantly in to areas outside of oral cancer thisis the ALTS programs definition for those that wish to know.
ALTS was a clinical trial to find the best way to help women and their doctors decide what to do about the mildly abnormal and very common Pap test results known as ASCUS and LSIL. About three million women in the United States are diagnosed with ASCUS and LSIL each year. Organized and funded by the National Cancer Institute, ALTS included more than 5,000 women. It began in November 1996 and concluded at the end of 2000. Data analysis of the trial's findings is ongoing.

ASCUS stands for atypical squamous cells of undetermined significance and LSIL for low-grade squamous intraepithelial lesions. Most of these mild abnormalities will go away without treatment, but some may signal a precancerous condition or, rarely, cancer, ALTS looked at three ways to manage these abnormalities:
immediate colposcopy (magnified viewing and testing of the cervix)
repeat Pap tests
testing for human papillomavirus (HPV), an infection linked to cervical cancer